Agilent Technologies to Separate into Two Public Companies
Agilent Technologies (Santa Clara, California) plans to separate into two publicly traded companies: one in life sciences, diagnostics, and applied markets that will retain the Agilent name, and another that will encompass Agilent?s current portfolio of electronic measurement products.
Agilent Technologies (Santa Clara, California) plans to separate into two publicly traded companies: one in life sciences, diagnostics, and applied markets that will retain the Agilent name, and another that will encompass Agilent’s current portfolio of electronic measurement products.
The new electronic measurement company will be an electronic measurement company in major markets including communications, aerospace and defense, and industrial, computers, and semiconductors.
Agilent says it believes that the separation will result in material benefits to the standalone companies, including greater management focus on the distinct businesses of life sciences, diagnostics, and applied markets, and electronic measurement; ability for the life sciences, diagnostics, and applied markets company to devote resources to the higher-growth life sciences, diagnostics, and applied markets business, while reducing exposure to the more cyclical electronic measurement industry; ability for the electronic measurement company to devote resources to its own growth that were previously used to capitalize life sciences, diagnostics, and applied markets; and two independent and unique investment profiles. Additionally, both companies will be well capitalized, having strong balance sheets and investment-grade profiles with target debt-to-EBITDA ratios below 2.0x.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
